Bayer (ETR: BAYN), a multinational pharmaceutical and life sciences company headquartered in Germany, has announced a strategic partnership with Hologic (NASDAQ: HOLX), a leading women’s health specialist. The collaboration aims to develop a contrast-enhanced mammography (CEM) solution that serves as a cost-effective adjunct to traditional mammography for breast cancer diagnosis. The project will integrate Bayer’s advanced contrast delivery system with Hologic’s state-of-the-art mammography technology, marking a significant step towards enhancing breast cancer detection capabilities.- Flcube.com
Recent news:
-
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement -
Abbott Laboratories' Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment -
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy -
Genmab's Tivdak Approved in Japan for Advanced Cervical Cancer Treatment -
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
